Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epstein-Barr virus gp350-ferritin vaccine
- Development stage
- Phase 2
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Epstein-Barr virus gp350-ferritin vaccine is a nanoparticle-based investigational vaccine designed to prevent infection by the Epstein-Barr virus (EBV) and its associated clinical manifestations, such as infectious mononucleosis. Developed by the NIAID Vaccine Research Center (VRC), the vaccine utilizes a self-assembling ferritin nanoparticle platform to display the EBV envelope glycoprotein gp350 in a multivalent fashion. gp350 is the most abundant protein on the surface of the virus and is the primary ligand used by EBV to attach to and infect B lymphocytes via the CD21 receptor. By presenting gp350 on a nanoparticle, the vaccine mimics the repetitive surface structure of a virus, which significantly enhances the induction of potent neutralizing antibodies compared to monomeric protein vaccines. It is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, and immunogenicity in healthy adults.
- Other names
- EBV gp350-ferritin nanoparticle vaccinegp350-ferritin nanoparticle vaccinegp-350-ferritin nanoparticle vaccinegp 350-ferritin nanoparticle vaccineFerritin-based EBV vaccine
02
Targets
gp350 (Epstein-Barr virus glycoprotein 350)EBV gH/gL (Epstein-Barr virus glycoprotein H/glycoprotein L complex)
Beyond the preview
Go deeper on Epstein-Barr virus gp350-ferritin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus gp350-ferritin vaccine.